Anil Chhettry, Ph.D., brings more than 25 years of expertise in the development of small molecule and peptide new chemical entities (NCEs) across oral, injectable, and inhalation dosage forms. He has led Chemistry, Manufacturing, and Controls (CMC) efforts for a broad range of investigational new drug (IND) applications, contributing to the successful approval of more than ten new drug applications (NDAs) across multiple therapeutic areas. Before joining Latigo Biotherapeutics, Anil held leadership roles at BioVie, Turning Point Therapeutics, Allergan, and Forest Laboratories, where he played a pivotal role in advancing complex development programs from preclinical stages through commercialization. Anil holds a Ph.D. in Pharmaceutics and Pharmaceutical Chemistry from the University of Utah.